Sanofi's chlamydia vaccine fast-tracked by FDA

A new mRNA vaccine is in the starting blocks – and once again at an rapid pace. This time it is not intended to protect against a virus, but against the sexually transmitted bacterial infection Chlamydia caused by Chlamydia trachomatis. The US Health Authority FDA has awarded the candidate of the French pharmaceutical giant Sanofi the so-called fast-track status (as already then with the experimental mRNA gene syringes at Corona), which is inten…

The US FDA has awarded fast-track status to an mRNA vaccine from Sanofi to prevent chlamydia infections, which is intended to develop ... The post Against chlamydia: Now the next mRNA vaccine is to be approved in an emergency procedure appeared first on Apollo News.

FDA grants fast track designation to chlamydia vaccine candidate - Pharmafile

The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection caused by the bacterium Chlamydia trachomatis. Sanofi is an international pharma and healthcare company, providing vaccination […] The post FDA grants fast track designation to chl…

Sanofi's chlamydia vaccine fast-tracked by FDA

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection gains USFDA fast track designation - Express Pharma

The US Food and Drug Administration (FDA) has granted fast-track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need. The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. …